>
>
Market research for novel oncology drug with NGS vs. IHC diagnostic strategy
Service Areas
Therapeutic Areas
Client Type
Mid-size Biotech
Client Problems
-
A mid size biotech company has a drug targeting a rare cancer mutation and wanted to plan an (ideal) CDx test to accompany the drug launch
-
They wanted to determine the current usage and future adoption of different molecular diagnostic platforms (single analyte, NGS and liquid biopsy)
-
Understand the pro’s and con’s of each platform and determine stakeholders (payers and physicians) perceptions
What We Did
-
Determined treatment flow and molecular diagnostics buy-in process
-
Conducted primary market research with stakeholders (oncologists, pathologists, and payers; N=31)
-
Secondary market research to analyze the market and competition
-
Mapped the niche and adoption of diagnostic platforms (single analyte, NGS, liquid biopsy) in academic vs commercial laboratories
Our Results And Insight
-
Patient flow and diagnostic tests buy-in process
-
Determined the drivers and barriers for NGS adoption
-
Current use trends and stakeholder opinions of solid NGS, liquid NGS, and IHC
See other case studies
Service Areas Details
Market Research (Quantitative and Qualitative Study)
Therapeutic Areas Details
Oncology (diagnostics, NGS, Solid Tumor)